Hey Mason! Thank you for the detailed response. My question wasn’t so much around: does FTO inhibition = m6a up, but asking how many degrees of separation are acceptable clinically. I.e - if Bisantrene is shown to be an FTO inhibitor in patients, then is it appropriate to claim (commercially, clinically) that Bisantrene upregulates m6a? This is in a context where we only measure pre and post Bisantrene FTO, not m6a levels. To that point, are we intending on measuring both in our lead in?
Hey Mason! Thank you for the detailed response. My question...
-
- There are more pages in this discussion • 124 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.67 |
Change
-0.080(4.58%) |
Mkt cap ! $285.2M | |||
| Open | High | Low | Value | Volume |
| $1.78 | $1.78 | $1.62 | $212.3K | 125.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1213 | $1.66 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.67 | 405 | 1 |
View Market Depth
| Last trade - 15.14pm 03/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |